Creatd Inc. has completed the sale of its remaining 80% equity stake in subsidiary Fly Flyte to Catheter Precision Inc., a New York Stock Exchange-listed company. The transaction provides Creatd with approximately $6 million in cash and nearly $6 million in Convertible Preferred Stock of Catheter Precision, significantly strengthening the company's balance sheet.
This sale aligns with Creatd's established strategy of developing turnkey operating solutions that prepare businesses for public market listings while maintaining minority interests. The transaction positions Creatd as a significant shareholder in Catheter Precision, adding NYSE-listed equity to its growing portfolio of public and private positions across diversified industries. Creatd's operational infrastructure, supported by technology and artificial intelligence, helps companies overcome structural hurdles and mature into institutionally viable enterprises.
Creatd acquired Fly Flyte approximately one year ago after initiating due diligence in the fourth quarter of 2024. The company implemented a disciplined turnaround strategy focused on operational optimization, technology integration, and targeted revenue growth, positioning Fly Flyte for acquisition by a nationally-listed platform. While the initial acquisition utilized financing and OTC Pink Sheet common stock, the exit consideration consists of cash and preferred equity in a New York Stock Exchange-listed company.
Jeremy Frommer, Chairman and CEO of Creatd Inc., stated that the company will continue pursuing its national exchange listing strategy this year without relying on traditional financing structures that often consume companies lacking balance sheet value. The recent reverse split, completed without accompanying financing, represented an important step toward meeting national exchange listing requirements. Frommer noted that this asset sale provides the capital needed to complete the next phase of the company's development.
Creatd creates balance sheet value through acquisition and incubation strategies for exchange-listed entities, where operating businesses can develop and position themselves for long-term success. The company simultaneously builds value from a portfolio of investments leveraging proprietary technology and processes. Frommer described Creatd as one of the few turnaround-focused publicly traded platforms in the small-cap and micro-cap merger and acquisition space, with intentions to institutionalize this model as the company expands its platform.
The company identifies significant opportunity in addressing structural gaps created by middle market contraction over the past two decades. Many public companies today lack the infrastructure and support needed to reach their full potential. Creatd is building a platform that helps companies stabilize, scale, and ultimately reach national exchange listings while creating lasting value. The strategic relationship between Creatd and Catheter Precision will continue through ongoing collaboration in aviation and electric vertical takeoff and landing logistics platform development.
For more information about Creatd Inc., visit https://www.creatd.com. Information about Fly Flyte is available at https://www.flyte.travel. The latest news and updates relating to Creatd are available in the company's newsroom at https://tinyurl.com/crtdnewsroom.
